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Abstract: Background: Multiple sclerosis (MS) is a chronic neurodegenerative disease of an 
inflammatory, demyelinating and autoimmune nature. Diets with a high caloric density could be 
especially relevant in terms of the pathogenesis related to an increase in adipose tissue that is 
metabolically active and releases mediators, which can induce systemic inflammation and an 
increased oxidation state. The aim of this study was to analyse the eating habits related to calorie 
intake and their impact on abdominal obesity associated with anthropometric variables, the activity 
of the oxidation marker paraoxonase 1 (PON1), and interleukin 6 (IL-6) levelsin MS patients. 
Methods: An analytical and quantitative observational study was conducted with a population of 
57 MS patients. The dietary-nutritional anamnesis was gained through the Food Frequency 
Questionnaire and a food diary. Diet and eating habits have been analysed through the Easy Diet–
Programa de gestión de la consulta® software. Anthropometric measurements were taken in order 
to determine the presence of abdominal obesity. In addition, PON1 was quantified in serum by 
means of automated spectrophotometric assays and IL-6 was quantified using the ELISA technique. 
Results: A normal calorie intake was determined for women, yet a slightly lower intake was 
observed in men. Carbohydrate consumption was below what was established, and protein and 
lipids were over, in both cases. Furthermore, most patients had abdominal obesity, with 
significantly higher body mass index (BMI), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), 
fat percentage and IL-6 levels. IL-6 is greatly correlated with waist circumference and WHtR. 
Conclusion: MS patients’ nutrient intake shows an imbalance between macronutrients. This seems 
to favour the abdominal obesity associated with high values of proinflammatory IL-6 that is not 
correlated with a lower activity of PON1.  
Keywords: multiple sclerosis; feeding behaviour; anthropometry; PON1 human protein; interleukin 
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1. Introduction 
Multiple sclerosis (MS) is a neurodegenerative disease of an inflammatory nature and of an 
autoimmune cause that progresses with damage to the myelin that covers neurons [1]. Clinically 
speaking, MS patients show functional disabilities associated with muscle mass loss and an increase 
in fat mass [2]. 
The patients’ nutritional condition can affect the clinical development of the disease [3], 
especially functional disability as it is related to anthropometric parameters, such as body mass index 
(BMI) and waist circumference [4]. In this sense, abdominal fat accumulation is particularly 
important, as it has a direct contribution to the chronic inflammation state of the disease [5], mediated 
by the production of proinflammatory cytokines [6]. Amongst the cytokines related to MS, 
interleukin 6 (IL-6) takes the spotlight, due to its high levels in blood serum in MS patients [7] and 
the fact that it is related to the pathogenesis of the disease [8]. In addition, IL-6 is positively correlated 
with obesity [9], and especially with an increase in abdominal fat [10]. These metabolic alterations 
have an influence on oxidation state, modifying biochemical markers that are also related to 
inflammation, such as the enzyme paraoxonase 1 (PON1). Low levels of PON1 in serum are 
associated with the development of neurodegenerative diseases [11] and specifically with MS [12]. 
PON1 acts by inhibiting the oxidation of LDLs, preventing cytokine production from being triggered 
[13], which makes it an inflammatory marker with antioxidant properties [14] and proving to be 
especially efficient to assess the metabolic state [15]. 
In this sense, previous studies indicate that nutritional alterations occur among these patients 
[16]. Thus, it has been found that patients perceive how the severity of the daily manifestations of the 
symptoms of their disease is directly related to the excessive consumption of meat, fatty foods and 
processed sugars [17].Specifically, in pediatric MS patients, diets with high levels of fat increase the 
risk of [18].However, and despite the importance of diet for pathology, nutritional status and eating 
habits in MS patients have not been studied in depth, as of yet. Taking this into account, the aim of 
this study is to analyse the eating habits related to calorie intake and its impact on the abdominal 
obesity associated with anthropometric variables, PON1 activity and IL-6 levels in serum. In addition, 
we aim to determine the possible correlation of IL-6 levels with these anthropometric and biochemical 
parameters. 
2. Materials and Methods 
Across-sectional, analytical and quantitative observational study was conducted. 
2.1. Subjects 
In order to obtain the population sample, we contacted the main state-wide MS associations 
which informed their members on the nature of the study. The following selection criteria were 
applied to the 72 people interested in participating in the study: patients over 18 years of age 
diagnosed with MS at least 6 months ago and treated with glatiramer acetate and interferon beta. 
Moreover, the exclusion criteria included: pregnant or breastfeeding women, patients with 
tracheotomy, stoma or with short bowel syndrome, patients with dementia, evidence of alcohol or 
drug abuse, with myocardial infarction, heart failure, cardiac dysrhythmia, symptoms of angina or 
other heart conditions, patients with kidney conditions with creatinine levels two times higher than 
normal markers, patients with elevated liver markers three times higher than normal or with chronic 
liver disease, patients with chronic metabolic diseases, patients with acromegaly, patients with 
polycystic ovary syndrome or MS patients who were included in other researches with experimental 
drugs or treatment. 
2.2. Statistical Analysis 
A statistical analysis was performed with the SPSS v.23 (IBM Corporation, Armonk, NY, USA) 
tool. The first step had the objective of estimating the distribution of the variables investigated 
through statistical methods in order to assess normality, including the Kolmogorov—Smirnov Test. 
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This analysis demonstrated the non-normal distribution of all the scale variables that had been 
studied. Therefore, the chi-square test and the Mann–Whitney U test were used to analyse categorical 
and numerical data, respectively. Finally, the Spearman test was used to find a possible correlation 
between the variables. A p-value below 0.05 was considered to be significant. Data are presented as 
mean ± standard deviation, or the number of patients and percentage. 
2.3. Procedure 
Once the sample was obtained, the volunteers and their families received detailed information 
on the study. The participants then signed an informed consent form after accepting to take part in 
the study.  
2.4. Measurements 
The following measurements were taken throughout the study: 
2.4.1. Dietary-Nutritional Anamnesis. 
The Food Frequency Questionnaire was used [19], which gave us information on how often 
different food groups were consumed: dairy products, vegetables, fruit, juices, nuts, meat, fish, 
seafood, eggs, tubers, rice, legumes, pasta, cold meats and sausages, snacks, pastries and biscuits, 
chocolate bars, soft drinks, fermented alcohol and distilled alcohol. The self-administered 
questionnaire asked about how oftencertain food groups were usually consumed in a week. 
In addition to using a food diary, each patient registered their solid and liquid food intake for 7 
days. This period of time enabled us to gather sufficient information on the patients’ normal diet, 
minimising the risk of bias associated with choosing one day a week [20]. Patients wrote down the 
type of food they consumed, as well as all the different ingredients used to make each and every dish. 
Each participant also took note of the amount that was consumed per intake, indicating the 
household measurement (a cup, a portion, a glass, a tablespoon, a slice, a handful, a plate, a 
ladleful…) or the exact weight of the food or drink. In order to make it easier for them to complete 
the task, patients were provided with information regarding the weight for each portion and the most 
common household measurements [21]. 
2.4.2. Diet and Eating Habit Analysis.  
Taking into account the patients’ food diary over 7 days and the Food Frequency Questionnaire, 
the quality of the diet was calibrated by using the Easy Diet–Programa de gestión de la consulta® 
software. With this software, a nutrition profile containing the daily averageof energy intake, total 
proteins, carbohydrates, carbohydrate profile (simple carbohydrates), total lipids, lipid profile 
(monounsaturated, saturated and polyunsaturated fatty acids), cholesterol and percentage 
distribution of macronutrients (proteins, lipids and carbohydrates)was obtained from the meals 
introduced to the program by the nutritionists. Additionally, in order to assess whether the diet was 
adequate or not, DRI (Dietary Reference Intake) from “Ingestas de referencia para la población 
Española”[22] and “Consenso de la Sociedad Española de NutriciónComunitaria (SENC)”[23] were 
taken as guidelines. 
2.4.3. Identification of Abdominal Obesity and Anthropometric Variables. 
Body weight, height, waist circumference and hip circumference were measured following the 
protocol established by The International Society for the Advancement of Kinanthropometry (ISAK) 
[24] by an ISAK level 3 certified anthropometrist. A portable clinical scale SECA model, with a 150–
200 kg capacity and 100 g precision was used, as well as a stadiometer, model SECA 220 Hamburg, 
Germany, with a 0.1 cm precision and a metal, inextensible and narrow anthropometric tape, model 
Lufkin W606PM with 0.2 mm precision [25]. 
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The following were calculated with the obtained data: BMI [26], waist-to-hip ratio (WHR) [27] 
and waist-to-height ratio (WHtR). Abdominal obesity was identified based on WHtR when it was 
over 0.5 [28]. 
2.4.4. Biochemical Analysis 
Blood samples were taken from the antecubital vein at 11 a.m. on an empty stomach and were 
collected in BD Vacutainer Plus serum blood collection tubes (ref. 367815). The samples were then 
kept at room temperature for 30 min in order to coagulate. The coagulated part was then separated 
by centrifuging the samples at 4000 rounds/min for 10 min in a refrigerated centrifuge. After 
centrifuging, the supernatant liquid was transferred to 0.5 mL aliquots that were frozen and stored 
at −80 °C. Finally, once the samples thawed, the concentration of IL-6 in serum was determined by 
means of the ELISA technique (R&D Systems). PON1 activity was determined by using 4-nitrophenyl 
acetate with an automatic clinical biochemistry analyser (Olympus A 400, Tokyo, Japan) [29]. 
2.4.5. Expanded Disability Status Scale (EDSS) 
This scale is used to assess functional disability in MS patients [30]. It is an ordinal scale based 
on a neurological examination of the eight functional systems (pyramidal, cerebellar, brainstem, 
mental, sensory, visual, bowel and bladder), together with assessing walking capacity, which 
provides a disability index between 0 and 10 as a result. In terms of calculation, 0 is understood as 
having normal health and 10 is understood as death by MS. 
2.5. Ethical Concerns 
The study was developed in accordance with the Declaration of Helsinki [31], with the prior 
approval of the protocol by the Human Research Committee of the University of Valencia of the 
Experimental Research Ethics Committee (procedure number H1512345043343). Participants were 
provided with a written informed consent form after being informed of the procedures and the nature 
of the study. 
3. Results 
After applying the selection criteria indicated in the Material and Methods section, and once 
some patients had abandoned the intervention, this study analysed a sample of 57 MS patients with 
an average age of 47.04 years, of which 66.7% were women and 33.3% were men. Thirty-seven 
patients had relapsing-remitting MS and 14 had secondary progressive MS, and with a functional 
capacity of 3.86±2.0 in the EDSS test.  
Biochemical markers (IL-6 and PON1) and anthropometric variables (weight, height, BMI, waist 
circumference, hip circumference, WHR and WHtR) are shown in Table 1 below.  
Table 1. Biochemical and anthropometric values analysed in the population sample. 
 
Women Men Total 
Mean SD Mean SD Mean SD 
IL-6 (pg/mL) 3.44 3.07 3.96 4.21 3.43 3.27 
PON1(UI/L) 2.80 0.70 3.06 0.60 2.86 0.68 
Weight (kg) 67.37 13.91 75.59 16.28 69.94 15.04 
Height (cm) 162.00 6.60 171.84 6.35 165.26 7.91 
BMI (kgm2) 25.80 5.10 25.69 5.92 25.70 5.31 
Waist circumference (cm) 96.18 13.13 94.49 10.37 95.40 11.81 
Hip circumference (cm) 108.70 12.45 98.81 10.69 104.14 12.56 
WHR 0.89 0.09 0.96 0.08 0.92 0.09 
WHtR 0.60 0.08 0.55 0.07 0.58 0.08 
Il-6: Interleukin 6 (mean value of normal IL-6 1.4 pg/ml); PON1: Paraoxonase 1; BMI: Body Mass 
Index; WHR: waist-to-hip ratio; WHtR: waist-to-height ratio; SD: Standard Deviation. 
Nutrients 2020, 12, 744 5 of 10 
 
3.1. Description of Eating Habits  
In accordance with the data obtained and once the daily diet and eating habits of the population 
of the study were analysed, the mean calorie intake for women was 1917.11 kcal and 2312.04 kcal for 
men.  
When analysing the percentage distribution of ingested macronutrients regarding the total 
calorie volume, with regards to lipids, 42.14% was observed in women and 41.96% in men, of which 
the mean intake of monounsaturated fatty acids was 34.25% for women and 37.56% for men, 
polyunsaturated fatty acids was 26.77% for women and 25.52% for men, and saturated fatty acids 
was 29.42% for women and 28.55% for men. Finally, the mean for cholesterol in women was 299.27 
mg and 356.88 mg for men (Table 2). In terms of carbohydrate intake, it was 38.61% for women and 
40.04% for men, with a mean percentage of simple carbohydrates intake of 50.66% for women and 
46.94% for men (Table 2). Regarding proteins, women had an intake of 23.81%, while men ingested 
29.79% of the total calorie volume (Table 2).  
Table 2. Description of eating habits and daily calorie intake of the population of the study. 
 




Mean SD Mean SD 
Energy (kcal) 1917.11 399.74 1875–2300 2312.04 468.91 2400–2850 
Proteins (g)  91.94 20.70 46 94.16 17.68 56 
Proteins (%) 23.81 6.70 10–20 29.79 7.44 10–20 
Lipids (%) 42.14 5.52 30–35 41.96 3.31 30–35 
MUFAs (%) 34.25 3.60 20 37.56 4.15 20 
PUFAs (%) 26.77 5.12 5 25.52 5.35 5 
SFA (%) 29.42 6.29 7–8 28.55 5.05 7–8 
Cholesterol (mg) 299.27 82.80 <300 356.88 129.10 <300 
Carbohydrates (g) 182.83 38.40 130 227.87 61.18 130 
Carbohydrates (%) 38.61 5.15 50–55 40.04 4.10 50–55 
Simple carbohydrates (%) 50.66 13.06 5–10 46.94 10.51 5–10 
DRI: dietary reference intake; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty 
acids; SFA; saturated fatty acids; SD: Standard Deviation. The percentage of the different 
macronutrients is expressed in reference with the total calorie volume. For simple carbohydrates, the 
percentage is expressed in reference with the total carbohydrate intake. 
3.2. Abdominal Obesity: Anthropometric and Biochemical Values  
As observed in Table 3, 50 patients (87.7%) were considered to have abdominal obesity, while 7 
(12.3%) were not classified as having it. 
The average levels of IL-6 are significantly higher when patients have abdominal obesity. There 
are no differences, however, in PON1 values between both groups of patients. BMI, body fat 
percentage, waist circumference, WHR and WHtR were substantially higher in patients with 
abdominal obesity, in comparison to those who did not. However, there were no differences in hip 
circumference. Finally, no important differences were observed between both groups in terms of age, 
weight and height. 
Table 3. Comparison between patients with or without abdominal obesity, according to waist-to-
height ratio (WHtR). 
 
Without abdominal obesity  
n = 7 
With abdominal obesity  
n = 50 
 
 Mean SD Mean SD Z p 
Age (years) 41.00 18.46 51.48 9.36 −1.547 0.122 
IL-6 (pg/mL) 1.77 0.80 3.79 3.43 −2.087 0.037 * 
Nutrients 2020, 12, 744 6 of 10 
 
PON1 (UI/L) 2.97 0.20 2.90 0.71 −0.386 0.700 
Weight (kg) 67.86 7.85 77.66 14.34 −1.555 0.120 
Height (cm) 172.80 4.49 165.47 9.17 −1.661 0.097 
BMI (kg/m2) 22.87 3.49 28.54 5.02 −2.394 0.017 * 
Waist circumference (cm) 80.90 5.27 97.53 10.99 −3.215 0.001 * 
Hip circumference (cm) 100.00 8.60 104.74 13.02 −0.673 0.501 
WHR 0.82 0.12 0.94 0.07 −2.338 0.019 * 
WHtR 0.47 0.02 0.59 0.07 −3.576 0.000 * 
Fat percentage  16.68 3.00 21.36 4.30 −2.052 0.040 * 
IL-6: Interleukin 6; PON1: Paraoxonase 1; BMI: Body Mass Index; WHR: waist-to-hip ratio; WHtR: 
waist-to-height ratio; Z: Mann–Whitney U test; *statistically significant differences p<0.05. 
3.3. Correlation between the Levels of IL-6, with the Analysed Anthropometric Variables and PON1. 
Regarding the correlations of IL-6 values as an inflammation marker with the analysed 
parameters, a positive correlation has been observed with waist circumference and WHtR. Therefore, 
the higher the levels of interleukin in serum, the higher the values of these variables. On the other 
hand, there is no significant correlation between BMI, WHR, hip circumference, fat percentage and 
PON1 (Table 4).  
Table 4. Correlations of Interleukin 6 (IL-6) with anthropometric variables and paraoxonase 1 (PON1). 








Coef. 0.318 0.217 0.407 0.194 0.291 0.413 0.235 
p 0.058 0.152 0.028 * 0.313 0.125 0.026 * 0.135 
IL-6: Interleukin 6; PON1: Paraoxonase 1; BMI: Body Mass Index; WHR: waist-to-hip ratio; WHtR: 
waist-to-height ratio; Coef.: Spearman's correlation coefficient; * statistically significant correlations 
p<0.05. 
4. Discussion 
Macronutrient intake can help or hinder the progression of diseases of a demyelinating nature 
such as MS [32], as it determines patients’ nutritional condition related to the pathology of the disease 
[3]. Due to this, our study analysed the calorie intake of the participants’ diet, and determined that 
women’s mean calorie intake is within the recommended dietary reference intake (DRI) (1875–2300 
kcal). However, the mean calorie intake for men was slightly lower than the recommended minimum 
(2400–2850 kcal) [22]. Nonetheless, percentage distribution in macronutrients (proteins, 
carbohydrates and lipids) did not meet the criteria of a balanced diet for both men and women [23], 
alongside a high disability level established by the EDSS test. In terms of carbohydrates, both sexes 
showed an intake lower than the recommended minimum (50%–55%) regarding the total calorie 
volume, yet simple carbohydrate intake was clearly higher than recommended (5%–10%) [23]. 
Nevertheless, the mean protein percentage for both men and women exceeds DRI recommendations 
(10%–20%) and the mean lipid percentage also surpasses the recommended values (30%–35%) [23]. 
In addition, the lipid profile for both sexes is characterised by an intake of MUFA, PUFA and SFA 
that does not comply with the DRI [22], alongside a higher consumption of cholesterol in men, which 
is in line with other publications by other authors [33]. In this sense, certain studies have observed 
that there is a link between the dietary intake of lipids and a higher prevalence and progression of 
MS [34–35]. These eating habits (and derived anthropometric characteristics) may be related to 
variables associated with the disease itself. These include treatment, mainly based on the 
administration of immunomodulators, and glucocorticoids that produce changes in food intake and 
weight gain [36], based on an increase in the percentage of abdominal fat [37]. In addition, the role of 
interleukin IL-6 itself, linked to the pathogenesis of the disease, has an important role in energy 
homeostasis [38] and whose acute central administration reduces intake in the short term, while when 
it is chronic central administration, it induces a reduction in intake and a loss in fat mass [39]. 
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An unbalanced diet alongside other environmental variables and factors, especially physical 
activity, could contribute to the anthropometric characteristics of the study population. Therefore, 
abdominal obesity was observed in a high number of patients, in which adipose tissue in the 
abdomen was associated with a significantly higher BMI, waist circumference, WHR, WHtR and fat 
percentage, in comparison to patients with no abdominal obesity. Similar results were registered in 
the study by Susan K. et al. 2017, in which BMI was positively associated with protein and lipid intake 
and negatively with carbohydrate intake in obese patients [40]. In addition, excessive simple 
carbohydrate intake is related to obesity and being overweight [41], as well as an increase in adipose 
tissue in the abdomen [42].  
In terms of the impact and influence of dietary intakes on the level of inflammation, we must 
highlight the fact that an excessive intake of lipids is related to oxidative stress and inflammation [43–
44].In addition, at a clinical level, one of the main symptoms of the disease is the motor-level 
alterations related to anthropometric alterations observed in the disease[45]. In this sense, an 
adequate intake of lipids has been observed to improve the feeling of fatigue in MS 
patients[46].Therefore, among the practical implications of this study, we found that establishing new 
dietary guidelines based on decreasing high lipid intakes could be a therapeutic strategy to reduce 
the inflammatory state associated with fatigue, involving a possible motor improvement. 
This decrease in lipid levels should also be accompanied by a lower percentage of simple 
carbohydrates that are also directly related to the production of proinflammatory cytokines [47]. 
Amongst these cytokines, our study determined it was IL-6 whose levels were high. These results 
coincide with those published by other authors [7]. Regarding the relation to anthropometric 
variables, there is a positive correlation with WHtR and waist circumference, while this did not 
happen with fat percentage, WHR, hip circumference and BMI. It seems to indicate that IL-6 is 
positively associated with fat accumulated in the abdominal area, as observed by other authors [10]. 
This is verified with significantly higher levels of interleukin in patients with this kind of obesity, 
which is also linked to the inflammatory status of the disease [5]. In this sense, the fundamental role 
of IL-6 in the inflammatory process of the pathology seems to be confirmed, which is in line with 
other results that links it to the pathogenesis of MS [8].  
However, we must highlight that, in our study, this increase in IL-6 is not correlated with PON1 
levels. This result indicates that the accumulation of fat, particularly in the abdomen area, is related 
to higher values of IL-6. However, it is not related to PON1 activity as a marker of total oxidation 
state. Thus, despite PON1 being a marker sensitive to anthropometric and metabolic improvements 
after nutritional treatment in MS patients, [48] and that its antioxidant activity is low in the disease 
[12], it is not a good marker for oxidative stress associated to inflammation for this disease, coinciding 
with what has been observed by other authors [49]. 
5. Conclusions 
Regarding nutrient intake in MS patients, despite calorie intake being within (women) or slightly 
lower (men) than the recommended values, there is an imbalance with carbohydrate intake being 
lower and lipid and protein intake being higher than the established recommendations. This seems 
to favour abdominal obesity associated to high values of proinflammatory interleukin 6, which, 
however, is not correlated with a lower activity of the oxidation marker PON1.  
Despite these results, we have found that our study has its limitations, which include the fact 
that the number of patients was not very high and only MS patients from Spain have been considered. 
In this sense, we believe that it would be a good idea to conduct a study that covers patients from 
different countries, allowing to also compare and analyse the impact of different food characteristics 
from other nationalities and regions. In addition, we think that other markers should be analysed, 
both for inflammation and oxidation, in order to establish the possible adequacy when determining 
the influence of the anthropometric characteristics of this population. 
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